New York State Common Retirement Fund’s Relmada Therapeutics RLMD Stock Holding History

New York State Common Retirement Fund’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-192	Closed	-$472	–	3354
2023 Q2	$472	Sell	192 -11,958	-98%	-$33.1K	﹤0.01%	3366
2023 Q1	$27.5K	Sell	12,150 -209	-2%	-$721	﹤0.01%	3083
2022 Q4	$43.1K	Sell	12,359 -21,237	-63%	-$187K	﹤0.01%	3111
2022 Q3	$1.24M	Buy	33,596 +13,415	+66%	+$372K	﹤0.01%	1866
2022 Q2	$383K	Buy	20,181 +7,137	+55%	+$156K	﹤0.01%	2480
2022 Q1	$352K	Hold	13,044	–	–	﹤0.01%	2563
2021 Q4	$294K	Sell	13,044 -9	-0.1%	-$200	﹤0.01%	2721
2021 Q3	$342K	Buy	13,053 +39	+0.3%	+$1.04K	﹤0.01%	2669
2021 Q2	$417K	Buy	13,014 +114	+0.9%	+$3.96K	﹤0.01%	2699
2021 Q1	$454K	Hold	12,900	–	–	﹤0.01%	2501
2020 Q4	$414K	Hold	12,900	–	–	﹤0.01%	2437
2020 Q3	$485K	Hold	12,900	–	–	﹤0.01%	2227
2020 Q2	$577K	Buy	+12,900	New	+$545K	﹤0.01%	2135

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

New York State Common Retirement Fund's RLMD Position: Q3 2023 in Review

New York State Common Retirement Fund sold out of Relmada Therapeutics (RLMD) in Q3 2023, closing a stake of 192 shares — an estimated $472 sold.

New York State Common Retirement Fund first reported a position in RLMD in Q2 2020 and held it in 13 quarters. The position peaked at $1.24M in Q3 2022. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

New York State Common Retirement Fund reported no remaining Relmada Therapeutics position as of Q3 2023 after selling out during the quarter.
New York State Common Retirement Fund sold 192 Relmada Therapeutics shares in Q3 2023, an estimated $472.
New York State Common Retirement Fund first reported a position in Relmada Therapeutics in Q2 2020 and held it in 13 quarters.
New York State Common Retirement Fund's Relmada Therapeutics position peaked at $1.24M in Q3 2022.
87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on New York State Common Retirement Fund's 13F filing for Q3 2023, filed 7 Nov 2023.